Apoptosis repressor with caspase recruitment domain enhances survival and promotes osteogenic differentiation of human 
osteoblast cells under Zoledronate treatment

Hu,Longwei; Han,Jing; Yang,Xi; Wang,Yang; Pan,Hongya; Xu,Liqun

doi:10.3892/mmr.2016.5669

Apoptosis repressor with caspase recruitment domain enhances survival and promotes osteogenic differentiation of human osteoblast cells under Zoledronate treatment

Authors:
- Longwei Hu
- Jing Han
- Xi Yang
- Yang Wang
- Hongya Pan
- Liqun Xu
View Affiliations

Affiliations: Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China, Oral Bioengineering Laboratory/Regenerative Medicine Laboratory, Shanghai Research Institute of Stomatology, Shanghai Key Laboratory of Stomatology, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, P.R. China
Published online on: August 24, 2016 https://doi.org/10.3892/mmr.2016.5669
Pages: 3535-3542
Copyright: © Hu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Zoledronate is one of the most potent nitrogen-containing bisphosphonates which has been demonstrated to result in osteoblast apoptosis and impact osteogenic differentiation in vitro. This effect of Zoledronate on osteoblasts may partially explain bisphosphonate‑associated osteonecrosis of the jaw, a serious complication associated with treatment with bisphosphonates. Apoptosis repressor with caspase recruitment domain (ARC) is a multifunctional inhibitor of apoptosis that is physiologically expressed predominantly in post‑mitotic cells such as cardiomyocytes, neurons and skeletal muscle cells. However, its effect on human osteoblasts remains unclear. The current study aimed to investigate the effects of ARC on human osteoblasts under the treatment of high concentrations of Zoledronate. ARC‑overexpressed human osteoblasts were established and were exposed to Zoledronate with different concentrations (0, 1 and 5 µM) in vitro. Cell numbers were detected using the MTT assay, and flow cytometry was used to identity cell apoptosis. Alkaline phosphatase staining, quantitative analysis and ectopic osteogenesis in nude mice were used to evaluate the osteogenic differentiation of ARC‑overexpressed osteoblasts. It was observed that ARC is able to reverse the inhibitory effect of Zoldronate on osteoblasts. ARC is additionally able to promote osteogenic differentiation of osteoblasts and inhibit their apoptosis. These observations suggest a critical role for ARC in the regulation of human osteoblasts under Zoledronate treatment.

View Figures

View References

1	Lewiecki EM: Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs. 71:791–814. 2011. View Article : Google Scholar : PubMed/NCBI
2	Baron R, Ferrari S and Russell RG: Denosumab and bisphosphonates: Different mechanisms of action and effects. Bone. 48:677–692. 2011. View Article : Google Scholar
3	Senaratne SG, Mansi JL and Colston KW: The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer. 86:1479–1486. 2002. View Article : Google Scholar : PubMed/NCBI
4	Kaiser T, Teufel I, Geiger K, Vater Y, Aicher WK, Klein G and Fehm T: Bisphosphonates modulate vital functions of human osteoblasts and affect their interactions with breast cancer cells. Breast Cancer Res Treat. 140:35–48. 2013. View Article : Google Scholar : PubMed/NCBI
5	Tenta R, Sourla A, Lembessis P and Koutsilieris M: Bone-related growth factors and zoledronic acid regulate the PTHrP/PTH.1 receptor bioregulation systems in MG-63 human osteosarcoma cells. Anticancer Res. 26:283–291. 2006.PubMed/NCBI
6	Hu L, Han J, Pan H and Xu L: High concentration of zoledronate inhibits osteogenesis differentiation and promotes apoptosis of human osteoblasts. China Journal of Stomatology. 24:389–394. 2015.
7	Li Y, Ge X and Liu X: The cardioprotective effect of postconditioning is mediated by ARC through inhibiting mitochondrial apoptotic pathway. Apoptosis. 14:164–172. 2009. View Article : Google Scholar : PubMed/NCBI
8	Li YZ, Liu XH, Zhu XM and Cai LR: ARC contributes to the inhibitory effect of preconditioning on cardiomyocyte apoptosis. Apoptosis. 12:1589–1595. 2007. View Article : Google Scholar : PubMed/NCBI
9	Hong YM, Jo DG, Lee JY, Chang JW, Nam JH, Noh JY, Koh JY and Jung YK: Down-regulation of ARC contributes to vulnerability of hippocampal neurons to ischemia/hypoxia. FEBS Lett. 543:170–173. 2003. View Article : Google Scholar : PubMed/NCBI
10	Koseki T, Inohara N, Chen S and Núñez G: ARC, an inhibitor of apoptosis expressed in skeletal muscle and heart that interacts selectively with caspases. Proc Natl Acad Sci USA. 95:5156–5160. 1998. View Article : Google Scholar : PubMed/NCBI
11	Jo DG, Jun JI, Chang JW, Hong YM, Song S, Cho DH, Shim SM, Lee HJ, Cho C, Kim DH and Jung YK: Calcium binding of ARC mediates regulation of caspase 8 and cell death. Mol Cell Biol. 24:9763–9770. 2004. View Article : Google Scholar : PubMed/NCBI
12	Brenner D and Mak TW: Mitochondrial cell death effectors. Curr Opin Cell Biol. 21:871–877. 2009. View Article : Google Scholar : PubMed/NCBI
13	Aino M, Nishida E, Fujieda Y, Orimoto A, Mitani A, Noguchi T, Makino H, Murakami S, Umezawa A, Yoneda T and Saito M: Isolation and characterization of the human immature osteoblast culture system from the alveolar bones of aged donors for bone regeneration therapy. Expert Opin Biol Ther. 14:1731–1744. 2014. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
15	Wang XJ, Huang H, Yang F, Xia LG, Zhang WJ, Jiang XQ and Zhang FQ: Ectopic study of tissue-engineered bone complex with enamel matrix proteins, bone marrow stromal cells in porous calcium phosphate cement scaffolds, in nude mice. Cell Prolif. 44:274–282. 2011. View Article : Google Scholar : PubMed/NCBI
16	Wiemer AJ, Tong H, Swanson KM and Hohl RJ: Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase. Biochem Biophys Res Commun. 353:921–925. 2007. View Article : Google Scholar : PubMed/NCBI
17	Xing LP and Boyce BF: Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun. 328:709–720. 2005. View Article : Google Scholar : PubMed/NCBI
18	Ebert R, Zeck S, Krug R, Meissner-Weigl J, Schneider D, Seefried L, Eulert J and Jakob F: Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone. 44:858–864. 2009. View Article : Google Scholar : PubMed/NCBI
19	Daubiné F, Le Gall C, Gasser J, Green J and Clézardin P: Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 99:322–330. 2007. View Article : Google Scholar : PubMed/NCBI
20	Manzano-Moreno FJ, Ramos-Torrecillas J, De Luna-Bertos E, Ruiz C and García-Martínez O: High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis. J Craniomaxillofac Surg. 43:396–401. 2015. View Article : Google Scholar : PubMed/NCBI
21	Cheong S, Sun S, Kang B, Bezouglaia O, Elashoff D, McKenna CE, Aghaloo TL and Tetradis S: Bisphosphonate uptake in areas of tooth extraction or periapical disease. J Oral Maxillofac Surg. 72:2461–2468. 2014. View Article : Google Scholar : PubMed/NCBI
22	Chen LH, Jiang CC, Watts R, Thorne RF, Kiejda KA, Zhang XD and Hersey P: Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein. Cancer Res. 68:834–842. 2008. View Article : Google Scholar : PubMed/NCBI
23	Mercier I, Vuolo M, Jasmin JF, Medina CM, Williams M, Mariadason JM, Qian H, Xue X, Pestell RG, Lisanti MP and Kitsis RN: ARC (apoptosis repressor with caspase recruitment domain) is a novel marker of human colon cancer. Cell Cycle. 7:1640–1647. 2008. View Article : Google Scholar : PubMed/NCBI
24	Wang M, Qanungo S, Crow MT, Watanabe M and Nieminen AL: Apoptosis repressor with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to nuclei. FEBS Lett. 579:2411–2415. 2005. View Article : Google Scholar : PubMed/NCBI